mal, T cell differentiation protein (MAL blood group)Genealiases: HLD28 · MVP17 · VIP17
Q-omics provides the consensus-scored MAL profile across patient tissues and cancer cell-line models. MAL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MAL is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MAL RNA expression shows 20,120 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, HNSC, and GBM as cancer lineages where MAL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAL survival associations across molecular data types. MAL RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAL RNA expression–survival associations across cancer types. High MAL expression shows unfavorable associations in UCEC, but favorable associations in LUAD, BRCA, KIRP, HNSC and UVM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MAL RNA expression.
This table summarizes MAL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MAL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAL shows lower tumor expression in HNSC, KIRC, STAD, COAD, KIRP and LUAD. The HNSC box plot shows higher MAL RNA expression in normal versus tumor tissue (log2 FC = −6.998, t-test p < 0.001).
This table shows molecular features associated with MAL in patient tissues and cancer cell lines. In patient samples, MAL shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
